Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Zardiw

03/27/24 9:13 PM

Post #5

Re: #4: @TimeFades - Choppy day shoulda just stuck with my morning short

$STOK Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:

Z

TimeFades

03/26/24 1:14 PM

Post #4

Choppy day shoulda just stuck with my morning short

TimeFades

03/26/24 1:13 PM

Post #3

Got bullish again and covered

TimeFades

03/26/24 11:36 AM

Post #2

Short from 12s

Invest-in-America Free

03/25/24 8:53 PM

Post #1

STOK: "Stoke Therapeutics (NASDAQ:STOK) stock shot up 70% in post-market trading Monday after the company reported positive results from studies for its drug STK-001 in the treatment of children and adolescents with Dravet syndrome, a genetic form of epilepsy. The biotech company said data from two Phase 1/2a studies and two open label extension, or OLE, studies showed “clinically meaningful effects” that included “substantial and durable reductions in convulsive seizure frequency."
https://seekingalpha.com/news/4083468-stoke-stock-soars-post-market-on-epilepsy-drug-data

Dravet Syndrome is an extremely RARE disease in the USA. And the above news does NOT specify nor suggest that STOK's (potential) treatment for Dravet Syndrome will or might have any applications for treatment of EPILEPSY at all. (Be very CAREFUL about news like the above.)